The effect of azilsartan on excercise capacity in hypertensive patients with sarcopenia

The effect of azilsartan on excercise capacity in hypertensive patients with sarcopenia - The effect of azilsartan on excercise capacity in hypertensive patients with sarcopenia

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012816

Enrollment

Registered

2014-01-20

Start date

2014-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

azilsartan amlodipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Hypertensive patients, 65yeas of age and older (2) The untreated hypertensive patients with BP beyond 140/90mmHg, or the uncontrolled hypertensive patients treated with single antihypertensive drugs other than RAS blockades (renin inhibitor, ACE inhibitor, ARB, aldosterone blocker) (3) Muscle mass of appendicular skeletal muscle measured by BIA methods less than 7.0kg//m2 in male, 5.8kg/m2 in female

Exclusion criteria

Exclusion criteria: (1) The subjects found difficult to perform functional therapy because of prior stroke or orthopedic disease. (2) The subjects who have past medical history of hypersensitivity to azilsartan or amlodipine (3) The subjects found offensive by attending physicians for this research

Design outcomes

Primary

Measure	Time frame
(1)Muscle strength of lower limbs (2)Muscle mass of appendicular skeletal muscle. (3)ABPM (4)Serum concentration of angiotensin 1-7	—

Secondary

Measure	Time frame
Serum myokine concentration	—

Countries

Japan

Contacts

Public ContactKoichi Yamamoto

Osaka university graduate school of medicine geriatric medicine and nephrology

kyamamoto@geriat.med.osaka-u.ac.jp06-6879-3852

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026